Xevant Unveils 2025 Drug Price Inflation White Paper: A Data-Driven Look at Rising Pharmaceutical Costs and Future Implications

LEHI, Utah--(BUSINESS WIRE)--Xevant, a leading provider of real-time data analytics for pharmacy benefit management, today announced the release of its 2025 Drug Price Inflation White Paper, providing key insights into the ongoing surge in pharmaceutical prices and what it means for payers, employers, and pharmacy benefit managers (PBMs).

As the cost of healthcare continues to escalate, the new year has brought a fresh wave of price hikes across the pharmaceutical landscape. Within the first two days of 2025, manufacturers increased the list prices of over 575 brand-name drugs, with a median increase of 4%. While modest on the surface, this rise has significant implications for patients and plan sponsors—particularly those impacted by the continued utilization of high-cost specialty drugs.

“List price increases grab headlines, but the real driver of inflation is utilization—especially in high-cost therapeutic classes with long-term use and expanding indications,” said Brandon Newman, CEO of Xevant. “To combat rising costs and maintain affordability, payers and PBMs must adopt a more strategic, data-driven approach to pharmacy benefit management.”

The white paper identifies the drugs most affected by inflation, their therapeutic categories, and explores future use cases that may drive further cost increases. It also outlines actionable strategies for mitigating financial impact, including:

• Biosimilar Adoption and Formulary Management
• Value-Based Contracting and Price Negotiations
• Patient Assistance and Affordability Programs
• Real-Time Analytics for Smarter Decision-Making

Xevant’s advanced analytics platform empowers consultants, brokers, health plans, employers, and PBMs with the tools to adapt quickly to inflationary pressures. With predictive cost modeling, real-time pricing visibility, and data-driven formulary adjustments, decision-makers can proactively manage pharmacy spending and ensure sustained access to essential treatments.

“Employers and plan sponsors can’t afford to be reactive,” Newman added. “Harnessing real-time data is no longer optional—it’s essential to navigating the complex and volatile drug pricing environment we’re facing in 2025.”

The full 2025 Drug Price Inflation White Paper is now available for download on Xevant’s website here.

About Xevant

Xevant is revolutionizing pharmacy benefits through real-time data analytics that empower smarter decisions, reduce costs, and improve patient outcomes. By delivering timely insights and automating complex analytics, Xevant helps healthcare organizations manage costs more effectively while enhancing the member experience.